Kidney patients needed for early COVID drug study

NCT ID NCT06698549

Completed Knowledge-focused Sponsor: Aligos Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This early study tests how the experimental COVID-19 drug ALG-097558 moves through the body in people with severe kidney problems compared to healthy volunteers. Twelve adults will take multiple doses of the drug. The goal is to see if kidney function affects drug levels and safety, not to test if it treats COVID-19.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ALG-097558
What this could lead to: If successful, this study could help determine safe dosing of ALG-097558 for COVID-19 patients with kidney issues.
What could go wrong: This is a very early Phase 1 study with only 12 people. It only looks at drug levels and safety, not whether the drug works against COVID-19. Results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Show contact details

Locations

Genesis Clinical Trials

Tampa, Florida, 33603, United States
Orlando Clinical Research Center

Orlando, Florida, 32809, United States
University of Miami

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.